ReviewFrontiers in pharmacology2025
Application of network pharmacology in traditional Chinese medicine for the treatment of cardiac diseases.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated Phytochemical and Pharmacological Insights intoPlants (Basel, Switzerland) · 2026Review
- Integrative Mechanistic Investigation of the Anticancer Effects ofMolecules (Basel, Switzerland) · 2026Article
- Crocus sativus L.-derived lauric acid-functionalized gold nanoparticles induce ferroptosis in HeLa cells and reverse M2 macrophage polarization via the PGE2/EP2/cAMP-PKA signaling pathway: a network pharmacology-based study.Frontiers in pharmacology · 2026Article
- Myocardial ischemia-reperfusion injury after acute myocardial infarction: spatiotemporal mechanisms and endotype-matched multi-target modulation by compounds from traditional Chinese medicine.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many innovative traditional Chinese medicines (TCMs) play a significant role in cardioprotection against cardiac diseases by addressing the basic causes of heart attack, which presents as a dual deficiency of qi and yang. Network pharmacology, offering a multi-dimensional perspective, can elucidate the specific mechanisms of the active components of TCM via a system pharmacology strategy. The methodology of network pharmacology is highly consistent with the modernization of TCM and provides a new perspective and theoretical basis for both basic research and its supplementary clinical research on cardiac diseases. This review summarizes the steps, databases, and software used in network pharmacology systematically. It also discusses the current achievements in applying network pharmacology to understand the mechanisms of some important TCMs (Huangqi, Renshen, and Danshen) and their active components in the context of cardioprotection against cardiac diseases based on a comprehensive literature search on PubMed. Anti-inflammation, anti-oxidation, anti-apoptosis, anti-pyroptosis, and regulation of the PI3K-AKT-mammalian target of the rapamycin (mTOR) signaling pathway were identified as the main mechanisms through which these TCMs exert cardioprotective effects. In addition, this approach provides new ideas for the cure of cancer-induced cardiac injury through network pharmacology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.